WST officer granted RSUs and stock options

Winters Chad reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Winters Chad reported acquisition or exercise transactions in this Form 4 filing.

WEST PHARMACEUTICAL SERVICES INC executive Chad Winters, VP and Chief Accounting Officer, reported equity awards on restricted stock units and stock options. He received 340 restricted stock units and 808 stock options as grants, both described as derivative securities with no cash paid per unit in these awards.

Each restricted stock unit represents a contingent right to receive one share of WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, creating a multi-year, performance- and service-linked compensation structure for this officer.

Insider Trade Summary

Grant/Award: 1,148 shares

Grant/Award 2 txns

Insider Winters Chad

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Rst. Stock Unit	340	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	808	$0.00	$0.00

Holdings After Transaction: Rst. Stock Unit — 340 contracts (Direct); Stock Option (Right to Buy) — 808 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.
2. F2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.
3. F3. The stock option vests in four equal annual installments beginning on March 1, 2027.

FAQ

What insider transactions did WST executive Chad Winters report on this Form 4?

Chad Winters reported equity award acquisitions, not open-market trades. He received 340 restricted stock units and 808 stock options as derivative grants, forming part of his compensation package, with no purchase price per unit disclosed in these awards.

How many restricted stock units were granted to Chad Winters at West Pharmaceutical (WST)?

Chad Winters was granted 340 restricted stock units. Each unit represents a contingent right to receive one share of WST common stock, subject to vesting conditions over time, aligning a portion of his compensation with the company’s future equity performance.

What stock option award did Chad Winters receive from West Pharmaceutical Services (WST)?

He received an award of 808 stock options classified as a derivative security. These options provide a right to buy WST common stock in the future, subject to vesting in four equal annual installments beginning March 1, 2027, if service conditions are met.

When do Chad Winters’ restricted stock units and stock options at WST begin vesting?

Both the restricted stock units and stock options begin vesting on March 1, 2027. They vest in four equal annual installments from that date, creating a long-term incentive structure designed to retain the executive over several years while linking rewards to continued service.

Is Chad Winters’ Form 4 for West Pharmaceutical (WST) a buy or sell transaction?

The Form 4 reflects grant or award acquisitions, not buys or sells. The transactions are coded as “A” for grant, covering 340 restricted stock units and 808 stock options, which are compensation-related derivative awards rather than open-market trading activity in WST common shares.

What role does Chad Winters hold at West Pharmaceutical Services (WST) in this Form 4 filing?

In this Form 4, Chad Winters is identified as an officer serving as VP, Chief Accounting Officer. The reported transactions document equity-based compensation grants, including restricted stock units and stock options, tied to his executive role and long-term incentive alignment with shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 11:22 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winters Chad

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	03/01/2026		A		340		(2)	(2)	Common Stock	340	$0	340	D
Stock Option (Right to Buy)	$254.34	03/01/2026		A		808		(3)	03/01/2036	Common Stock	808	$0	808	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.

3. The stock option vests in four equal annual installments beginning on March 1, 2027.

	/s/ Caitlin Hippeli, as an agent for Chad Winters	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.